Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Free Cash Flow (2016 - 2025)

Regenxbio has reported Free Cash Flow over the past 12 years, most recently at -$51.3 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$51.3 million for Q4 2025, down 56.78% from a year ago — trailing twelve months through Dec 2025 was -$124.9 million (up 28.88% YoY), and the annual figure for FY2025 was -$124.9 million, up 28.88%.
  • Free Cash Flow for Q4 2025 was -$51.3 million at Regenxbio, up from -$56.5 million in the prior quarter.
  • Over the last five years, Free Cash Flow for RGNX hit a ceiling of $326.9 million in Q4 2021 and a floor of -$85.7 million in Q1 2023.
  • Median Free Cash Flow over the past 5 years was -$51.1 million (2023), compared with a mean of -$31.6 million.
  • Peak annual rise in Free Cash Flow hit 2485.08% in 2021, while the deepest fall reached 125.7% in 2021.
  • Regenxbio's Free Cash Flow stood at $326.9 million in 2021, then plummeted by 113.72% to -$44.8 million in 2022, then grew by 6.59% to -$41.9 million in 2023, then rose by 21.92% to -$32.7 million in 2024, then plummeted by 56.78% to -$51.3 million in 2025.
  • The last three reported values for Free Cash Flow were -$51.3 million (Q4 2025), -$56.5 million (Q3 2025), and -$49.7 million (Q2 2025) per Business Quant data.